ClinicalTrials.gg
CompletedNCT00983255IV/SAD/MADUpdated May 19, 2016

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

A Phase 1 interventional study of TR-701 FA for injection, 200 mg/vial and TR-701 FA tablets in Bacterial Infections, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-19.

Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Bacterial Infections by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Merck & Co., Inc.

Enrollment
6th of 12
90 · median 83
Started
2009
the only one that year
Phase 1
3 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Bacterial Infections by Merck & Co., Inc, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 3 in phase 1, and was the 7th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 12 studies in Bacterial Infections by Merck & Co., Inc is open now. The open studies under Bacterial Infections, anywhere →

Where they have run

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Bacterial Infections by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single rising and multiple rising IV doses of TR-701 FA and to determine the absolute bioavailability of oral TR-701 FA following single oral and IV dose administrations in healthy adult subjects.

Read the detailed description

SAD/Part A.

  • All subjects in the Pilot Cohort will receive a single infusion of 50 mg TR-701 FA for injection in 250 cc of saline over 180 minutes.
  • Subjects in Cohort 1 will be randomized to receive a single infusion of placebo or 100 mg of TR-701 FA for injection in 250 or 500 cc of saline over 60 or 120 minutes.
  • Subjects in Cohort 2 will be randomized to receive a single infusion of placebo or 200 mg of TR-701 FA for injection in 250 or 500 cc of saline over 60 or 120 minutes.
  • Subjects in Cohort 3 will be randomized to receive a single infusion of placebo or 400 mg of TR-701 FA for injection in 250 or 500 cc of saline over 60 or 120 minutes.

MAD/Part B

  • Subjects in Cohort 4 will be randomized to receive once daily infusions of placebo or 200 mg of TR-701 FA for injection in 250 cc of saline over 60 minutes for 7 days.
  • Subjects in Cohort 5 will be randomized to receive once daily infusions of placebo or 300 mg of TR-701 FA for injection in 250 cc of saline over 60 minutes for 7 days.

BA/Part C

  • Subjects in Cohort 6 will receive a single 60 minute infusion of 200 mg TR-701 FA for injection in 250 cc of saline and a singe oral dose of 200 mg TR-701 FA tablet in an open-label crossover design.

Venous Tolerability/Part D

  • Subjects in Cohort 8 will receive once daily 60 minute infusions of 200 mg TR-701 FA for injection in 250 cc of saline for 3 days and once daily placebo infusions for 3 daysin a blinded crossover design.
03

Conditions studied

  • Bacterial Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • in good health
  • of 20 to 29.9 kg/m2
  • female subjects must be post menopausal for at least 1 year, surgically sterile, abstinent or agree to use an effective method of

Exclusion criteria

Exclusion Criteria:

  • history or clinical manifestation of any disorder
  • history of to any drug compound
  • history of stomach or intestinal surgery or resection
  • history of infections of unexplained frequency or severity
  • history of alcoholism or drug addiction within 1 year
  • use of any tobacco- or nicotine-containing products within 6 months
  • use of alcohol-, grapefruit-, caffeine-, or high tyramine-containing foods or beverages
  • use of any other medications
  • pregnancy, lactation, or breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    SAD/ Part A

    Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.

    Drug: TR-701 FA for injection, 200 mg/vial

  • Experimental
    MAD / Part B

    Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.

    Drug: TR-701 FA for injection, 200 mg/vial

  • Experimental
    Bioavailability / Part C

    TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.

    Drug: TR-701 FA for injection, 200 mg/vial · Drug: TR-701 FA tablets

  • Experimental
    Venous Tolerability/ Part D

    IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,

    Drug: TR-701 FA for injection, 200 mg/vial

Interventions

  • DrugTR-701 FA for injection, 200 mg/vial

    TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D

    Also known as: Torezolid Phospate

  • TR-701 FA will be given once orally as a 200 mg tablet in Part C.

    Also known as: Torezolid Phosphate Tablet

06

What researchers measure

Primary outcomes

  1. Safety Assessments

    Time frame: 10 days

Secondary outcomes

  1. To evaluate the pharmacokinetics of TR-701 and its microbiologically active moiety TR-700 after single and multiple IV doses of TR-701 FA

    Time frame: 10 days

  2. To determine the absolute bioavailability of oral TR-701 FA following single oral and IV dose administrations in healthy adult subjects

    Time frame: 4 days

07

Study locations

1 site
  • Covance Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Publications

  • Flanagan S, Fang E, Munoz KA, Minassian SL, Prokocimer PG. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy. 2014 Sep;34(9):891-900. doi: 10.1002/phar.1458. Epub 2014 Jul 3. PubMed 24989138 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2009
First posted
Sep 24, 2009
Start
Sep 2009
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Last update
May 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00983255
Responsible party
Sponsor
First posted
Sep 24, 2009
Start date
Sep 2009
Primary completion
Jan 2010
Completion
Jan 2010
Last update
May 19, 2016

Study contacts

Nicholas Siebers, MD
principal investigator · Covance Clinical Research Unit, Madison, WI, USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion